Progression of hepatic fibrosis after HCT for thalassemia major, according to iron and HCV status

This figure shows the probability of surviving without progression of hepatic fibrosis (percent, y axis) versus time after HCT (months, x axis) in 211 patients with thalassemia major who were not treated with iron chelation or antiviral therapy. Patients were stratified into six groups according to hepatic iron concentration (low: 0.5 to 5.6, medium: 5.7 to 12.7, high >12.7 mg/g dry weight) and HCV status (positive, negative). HCV-negative patients with low or medium hepatic iron levels did not show progression of fibrosis and were grouped together (uppermost curve, red).